News

Sofinnova puts €42m into Auris
Enlarge image

FinanceSwitzerlandFrance

Sofinnova puts €42m into Auris

18.04.2013 - Swiss drug developer Auris Medical has bagged €41.6m in a Series C financing.

The company has said it will use the funds to advance its two major therapeutics for the treatment of inner ear disorders, AM101 and AM111. Efficacy of esketamine (AM-101), a small molecule non-competitive blocker of the NMDA receptor, has been successfully tested in a Phase II trial on 240 patients with acute inner ear tinnitus. However, Phase IIb results will be tabled in later summer, according to the company. Peptidic JNK signalling blocker AM-111 has already shown proof-of-concept in a Phase II trial on 204 patients with acute sensineural hearing loss. Both drugs are administered by intratympanic injection with a biocompatible gel formulation. 

"Having established proof of concept in Phase IIb studies, we are now ready to move forward with our clinical development plans," said Auris chief Thomas Meyer. Californian Sofinnova Ventures and Paris-based Sofinnova Partners, which participated in the current financing round added Jim Healy, General Partner at Sofinnova Ventures, and Antoine Papiernik, Managing Partner at Sofinnova Partners, to Auris Medical's Board of Directors.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/sofinnova-puts-eur42m-into-auris.html

BusinessIreland

07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, Biogen will create up to 400 jobs at the new plant.

R&DNetherlandsSpainAustria

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

Events

All Events

Current issue

All issues

Product of the week

Products